Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P26
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -4.33% |
| Q3 2025 | -25.35% |
| Q2 2025 | 10.71% |
| Q1 2025 | -6.78% |
| Q4 2024 | -21.57% |
| Q3 2024 | 3.45% |
| Q2 2024 | 10.40% |
| Q1 2024 | 3.25% |
| Q4 2023 | -5.73% |
| Q3 2023 | -4.14% |
| Q2 2023 | 2.07% |
| Q1 2023 | -3.13% |
| Q4 2022 | -0.01% |
| Q3 2022 | -7.78% |
| Q2 2022 | 9.16% |
| Q1 2022 | -4.66% |
| Q4 2021 | -3.49% |
| Q3 2021 | 47.20% |
| Q2 2021 | 0.29% |
| Q1 2021 | 12.78% |
| Q4 2020 | 70.96% |
| Q3 2020 | 71.75% |
| Q2 2020 | 38.22% |
| Q1 2020 | -3.61% |
| Q4 2019 | -10.62% |
| Q3 2019 | 134.29% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |